Monopar Therapeutics stock price prediction: Support pressure looms at $81.33

Traders Union
All News
Stocks
Monopar Therapeutics slides 3% today

Highlights

MNPR/USD trades below its short- and medium-term moving averages, showing sustained selling pressure with longer-term support still present.
Momentum indicators remain strongly negative, with oversold readings dominating and only a short-term bounce possible due to overbought Stoch RSI.
Expected 2 to 3 day price range is $81.3256 to $91.3744, with further downside carrying very high probability unless $92.04 is broken.

Sustained seller control as technicals reinforce bearish momentum

On the technical side, MNPR is positioned beneath its MA-20 and MA-50, which highlights persistent selling pressure on both short- and medium-term timeframes. However, the stock trades above the MA-200, indicating possible longer-term support. The Ichimoku Kijun at $92.04 establishes immediate resistance for any upside attempt. MACD is in a strong sell configuration, while ADX confirms downward momentum and seller dominance. Both RSI (41) and CCI are at oversold levels, reinforcing the selling conditions, whereas Bull/Bear Power also points clearly to seller control on the intraday horizon. Stoch RSI is notably overbought, flagging the prospect of a short-term relief bounce within the broader weakness, while the Awesome Oscillator reads neutral—failing to validate either direction. Volatility is moderate and price has settled near session lows with a modest intraday gap.

Range-bound scenario likely as breakout risks remain

Over the next 2–3 days, price is expected to fluctuate within the $81.33 to $91.37 range, reflecting typical volatility for MNPR at current levels. The most probable scenario is sideways movement within this band. Should the stock break above $92.04, a push toward the next resistance zone could become possible. Conversely, a drop below $81.33 would likely open the way for additional downside in the short term.

Viktoras Karapetjanc, expert at Traders Union, sees Monopar Therapeutics showing technical weakness but notes that key long-term support remains intact. Despite a lack of fresh news, he interprets the oversold momentum and stable macro sentiment as reasons for confidence. The analyst believes sideways consolidation is favored with potential for an upside catalyst if resistance at $92.04 is cleared. "While sellers are in control for now, I see room for a relief bounce above $92.04 and remain constructive on MNPR’s near-term prospects."

Earlier, analysts noted that Monopar Therapeutics was experiencing persistent selling pressure in the short- and medium-term timeframes, while maintaining longer-term trend support. The current technical setup reinforces this view, with volatility expected to keep price action confined to the $81.33–$91.37 range in the near term and any break outside this band likely setting the tone for the next directional move.

Source of Data: MNPR Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.